Table 1.
Dosing and draw time characteristics of study participants contributing to immunogenicity analysis.
Figure 1.
Concentrations of serotype-specific IgG from sera collected post-primary from PCV7 and PCV13 recipients.
Figure 2.
Concentrations of serotype-specific IgG from sera collected post-booster from PCV7 and PCV13 recipients.
Table 2.
Percentage of participants who received PCV7 or PCV13 and achieved pneumococcal IgG antibody concentrations ≥0.35 µg/mL or ≥1.0 µg/mL.
Table 3.
Inhibition of serotype-specific 19A or 19F opsonophagocytic activity (GMTs) by purified polysaccharide following PCV7 or PCV13 immunization.
Table 4.
Inhibition of serotype-specific 6A, 6B and 6C opsonophagocytic activity (GMTs) by purified polysaccharide following immunization with PCV7 or PCV13 vaccine.